These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 21356260)

  • 1. Pulmonary delivery of therapeutic siRNA.
    Lam JK; Liang W; Chan HK
    Adv Drug Deliv Rev; 2012 Jan; 64(1):1-15. PubMed ID: 21356260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patents review in siRNA delivery for pulmonary disorders.
    Khatri NI; Rathi MN; Kolte AA; Kore GG; Lalan MS; Trehan S; Misra AR
    Recent Pat Drug Deliv Formul; 2012 Apr; 6(1):45-65. PubMed ID: 22264188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonviral pulmonary delivery of siRNA.
    Merkel OM; Kissel T
    Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhalable siRNA: potential as a therapeutic agent in the lungs.
    Durcan N; Murphy C; Cryan SA
    Mol Pharm; 2008; 5(4):559-66. PubMed ID: 18491918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary delivery of siRNA as a novel treatment for lung diseases.
    Kandil R; Merkel OM
    Ther Deliv; 2019 Apr; 10(4):203-206. PubMed ID: 30991921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-viral siRNA delivery to the lung.
    Thomas M; Lu JJ; Chen J; Klibanov AM
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):124-33. PubMed ID: 17459519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
    De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
    J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges.
    Ding L; Tang S; Wyatt TA; Knoell DL; Oupický D
    J Control Release; 2021 Feb; 330():977-991. PubMed ID: 33181203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
    Li SD; Huang L
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations.
    Bielski E; Zhong Q; Mirza H; Brown M; Molla A; Carvajal T; da Rocha SRP
    Int J Pharm; 2017 Jul; 527(1-2):171-183. PubMed ID: 28549971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in siRNA delivery in cancer therapy.
    Singh A; Trivedi P; Jain NK
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):274-283. PubMed ID: 28423924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery systems of small interfering RNA by systemic administration.
    Kawakami S; Hashida M
    Drug Metab Pharmacokinet; 2007 Jun; 22(3):142-51. PubMed ID: 17603214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations.
    Ngan CL; Asmawi AA
    Drug Deliv Transl Res; 2018 Oct; 8(5):1527-1544. PubMed ID: 29881970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanocarriers in effective pulmonary delivery of siRNA: current approaches and challenges.
    Bardoliwala D; Patel V; Javia A; Ghosh S; Patel A; Misra A
    Ther Deliv; 2019 May; 10(5):311-332. PubMed ID: 31116099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lyophilization and nebulization of pulmonary surfactant-coated nanogels for siRNA inhalation therapy.
    Merckx P; Lammens J; Nuytten G; Bogaert B; Guagliardo R; Maes T; Vervaet C; De Beer T; De Smedt SC; Raemdonck K
    Eur J Pharm Biopharm; 2020 Dec; 157():191-199. PubMed ID: 33022391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(lactide-
    Wu L; Wu LP; Wu J; Sun J; He Z; Rodríguez-Rodríguez C; Saatchi K; Dailey LA; Häfeli UO; Cun D; Yang M
    ACS Appl Mater Interfaces; 2021 Jan; 13(3):3722-3737. PubMed ID: 33439616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surfactant protein B (SP-B) enhances the cellular siRNA delivery of proteolipid coated nanogels for inhalation therapy.
    Merckx P; De Backer L; Van Hoecke L; Guagliardo R; Echaide M; Baatsen P; Olmeda B; Saelens X; Pérez-Gil J; De Smedt SC; Raemdonck K
    Acta Biomater; 2018 Sep; 78():236-246. PubMed ID: 30118853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNAi-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice.
    Gutbier B; Kube SM; Reppe K; Santel A; Lange C; Kaufmann J; Suttorp N; Witzenrath M
    Pulm Pharmacol Ther; 2010 Aug; 23(4):334-44. PubMed ID: 20362688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.